(Total Views: 612)
Posted On: 10/02/2024 2:44:42 PM
Post# of 148866
As soon as the relationship with the FDA was "restored," and in light of past mgmt being long gone, that statement should have been taken down.
It's absolutely an impediment to raising funds for the company, which in turn damages the clinical pipeline, and delays the drug reaching the people who need it. Who is the statement helping/protecting right now? If the lines of communication are truly "mended," the statement should be removed as Cytodyn moves forward.
This opening line simply isn't true: "It has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19." (See: Science Direct for more details.)
It's absolutely an impediment to raising funds for the company, which in turn damages the clinical pipeline, and delays the drug reaching the people who need it. Who is the statement helping/protecting right now? If the lines of communication are truly "mended," the statement should be removed as Cytodyn moves forward.
This opening line simply isn't true: "It has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19." (See: Science Direct for more details.)
(13)
(0)Scroll down for more posts ▼
